Patent 11,173,209: Antibody Compositions and Methods for Treating Cancer
United States Patent 11,173,209, granted on January 11, 2022, to Bristol-Myers Squibb Company, claims novel antibody compositions and their use in treating cancers, particularly those exhibiting a specific genetic mutation. The patent's core innovation lies in bispecific antibodies designed to engage both the programmed cell death protein 1 (PD-1) receptor and a tumor-associated antigen (TAA). This dual targeting mechanism aims to enhance anti-tumor immune responses by simultaneously blocking inhibitory immune checkpoints and directing immune effector cells to the tumor site.
What is the Primary Technological Advance Claimed?
The primary technological advance claimed in US Patent 11,173,209 is the development of bispecific antibodies that bind to both PD-1 and a tumor-associated antigen (TAA). Specifically, the patent defines antibodies that comprise two binding domains: one that binds to PD-1 and another that binds to a TAA. These antibodies are engineered to be expressed in a manner that facilitates simultaneous interaction with both targets, thereby eliciting a coordinated immune response.
What Specific Tumor-Associated Antigens are Covered?
The patent encompasses a broad range of tumor-associated antigens. Claim 1 defines a bispecific binding molecule comprising:
- A first binding domain that specifically binds to Programmed Cell Death Protein 1 (PD-1).
- A second binding domain that specifically binds to a tumor-associated antigen (TAA).
The patent further specifies that the TAA can be any TAA recognized by an antibody that inhibits the binding of the TAA to its cognate ligand. While specific examples of TAAs are not exhaustively enumerated in the independent claims, the specification provides context for the types of targets envisioned. For instance, the patent refers to the general understanding of TAAs that are overexpressed on cancer cells. Therapeutic applications mentioned in the specification often relate to cancers where checkpoint inhibitors have shown promise.
What are the Key Structural and Functional Elements of the Claimed Antibodies?
US Patent 11,173,209 defines bispecific antibodies with specific structural and functional attributes. The core elements include:
- Bispecificity: The antibody is designed to bind to two distinct antigens simultaneously.
- PD-1 Binding Domain: A component of the antibody that specifically interacts with the PD-1 receptor.
- TAA Binding Domain: A component of the antibody that specifically interacts with a tumor-associated antigen.
- Binding Affinity: The patent specifies that the binding affinity of the PD-1 binding domain is characterized by an equilibrium dissociation constant (KD) of less than or equal to 10 nM for human PD-1. This indicates a high affinity interaction.
- Inhibitory Function: The TAA binding domain is characterized by its ability to inhibit the binding of the TAA to its cognate ligand.
- Engineering for Dual Engagement: The bispecific binding molecule is engineered to facilitate simultaneous binding to PD-1 and the TAA, thereby enabling a dual mechanism of action.
The patent covers various formats for these bispecific antibodies, including single-chain variable fragments (scFvs), fragment antigen-binding (Fab) regions, and full-length immunoglobulin G (IgG) antibodies, as well as engineered formats designed for improved pharmacokinetics or tissue penetration.
What Cancers are Targeted by These Antibody Compositions?
The patent broadly claims the use of these bispecific antibody compositions for treating, preventing, or inhibiting the growth of cancer. The specification highlights that the TAA is preferably expressed on tumor cells. While specific cancer types are not explicitly limited in the independent claims, the context of PD-1 inhibition and TAA targeting points towards the treatment of various solid tumors and hematological malignancies where these pathways are implicated. The invention is particularly relevant for cancers that express the chosen TAA and where TAA expression can be leveraged to direct immune activity.
What are the Claims Regarding Pharmaceutical Compositions and Methods of Treatment?
US Patent 11,173,209 includes claims directed to pharmaceutical compositions containing the bispecific antibodies and methods of treating cancer.
Pharmaceutical Compositions
Claim 13 defines a pharmaceutical composition comprising:
- A bispecific binding molecule as defined in claim 1.
- A pharmaceutically acceptable carrier.
These compositions are formulated for administration to a subject for the treatment of cancer.
Methods of Treatment
Claim 14 describes a method of treating cancer in a subject, comprising:
- Administering to the subject a therapeutically effective amount of a bispecific binding molecule as defined in claim 1.
The method is described as treating cancer that expresses a TAA to which the bispecific binding molecule binds. Further dependent claims may specify particular dosages, administration routes, or patient populations, but the overarching method claim focuses on the administration of the bispecific antibody for therapeutic benefit.
What is the Intellectual Property Landscape for Bispecific Antibodies Targeting PD-1 and TAAs?
The patent landscape for bispecific antibodies, particularly those targeting immune checkpoints like PD-1 in combination with tumor-associated antigens, is highly active and competitive. Bristol-Myers Squibb, as the assignee of US Patent 11,173,209, is a significant player in this space, with existing approvals for PD-1 inhibitors like nivolumab (Opdivo).
Other major pharmaceutical companies and biotechnology firms are actively developing similar bispecific antibody platforms. Key competitors and their relevant programs (as of publicly available information and patent filings) include:
- Amgen: Has developed bispecific T-cell engagers (BiTEs) that target CD19 and CD3 for B-cell malignancies, and is exploring other bispecific formats.
- Roche (Genentech): Known for its PD-L1 inhibitor atezolizumab (Tecentriq) and is developing bispecific antibodies, including those targeting T-cell engagers.
- Merck & Co.: The developer of pembrolizumab (Keytruda), another major PD-1 inhibitor, is also investing in next-generation immunotherapies, likely including bispecific formats.
- Regeneron Pharmaceuticals: Has a portfolio of oncology therapeutics and is actively researching bispecific antibody technologies.
- Harbour BioMed: Is developing bispecific antibodies targeting various immune checkpoints and tumor antigens.
- Xencor: Focuses on engineering advanced antibody therapeutics, including bispecifics with improved properties.
The patent landscape is characterized by overlapping claims related to antibody structures, engineering techniques, targeting strategies, and therapeutic applications. Companies are seeking patent protection for novel bispecific formats (e.g., different linker technologies, Fc modifications for half-life extension or effector function tuning), unique TAA targets, specific combinations of targets, and methods of manufacturing.
Key aspects of the competitive landscape include:
- Patent Thickets: The development of multiple, overlapping patents by various entities can create patent thickets, making it challenging to navigate freedom-to-operate for new entrants.
- First-to-File System: The United States operates on a first-to-file system, meaning the first to file a patent application for an invention is generally granted the patent, provided it meets the patentability criteria.
- Claim Interpretation: The scope and enforceability of patent claims are subject to interpretation by courts, which can impact the effective protection afforded by a patent.
- Evergreening Strategies: Companies may pursue patent protection for incremental improvements or new formulations of existing therapies to extend market exclusivity.
US Patent 11,173,209 contributes to this complex landscape by securing intellectual property for a specific approach to bispecific antibody design targeting PD-1 and TAAs, potentially influencing the development and commercialization strategies of other players in the immuno-oncology field.
What are the Potential Implications for Drug Development and Investment?
The issuance of US Patent 11,173,209 has several potential implications for drug development and investment in the immuno-oncology space:
- Market Exclusivity: The patent grants Bristol-Myers Squibb a period of market exclusivity for the specific bispecific antibody compositions and methods claimed. This exclusivity can last up to 20 years from the patent filing date, subject to patent term extensions and other provisions. This provides a significant competitive advantage.
- Freedom to Operate: Companies developing bispecific antibodies that fall within the scope of these claims may face challenges in obtaining freedom to operate. They will need to carefully analyze their own antibody designs and therapeutic targets to ensure they do not infringe on the patent's claims.
- Licensing Opportunities: The patent may create opportunities for licensing agreements. Other companies may seek to license the technology from Bristol-Myers Squibb to incorporate it into their own development programs, potentially through collaborations or partnerships.
- Strategic Investment Focus: Investors seeking to identify promising opportunities in immuno-oncology will need to consider the patent landscape. Patents like 11,173,209 highlight areas of innovation and potential market dominance. Investments may be directed towards companies with strong IP portfolios or those developing technologies that complement or circumvent existing patents.
- R&D Direction: The patent reinforces the strategic importance of developing bispecific antibodies that combine immune checkpoint inhibition with targeted tumor cell engagement. This may encourage further R&D into novel combinations of targets and advanced antibody engineering techniques to differentiate new products.
- Competitive Differentiation: The existence of this patent may push competitors to focus on developing bispecific antibodies with different target combinations, novel mechanisms of action, or alternative therapeutic modalities to avoid infringement and establish their own intellectual property.
Key Takeaways
- US Patent 11,173,209 protects bispecific antibodies designed to bind simultaneously to PD-1 and a tumor-associated antigen (TAA).
- The innovation centers on leveraging dual targeting to enhance anti-tumor immune responses.
- The patent covers a broad range of TAAs and various antibody formats.
- Claimed methods encompass the treatment of various cancers where the TAA is expressed.
- The patent landscape for bispecific immuno-oncology drugs is highly competitive, with numerous companies actively developing similar technologies.
- The patent provides market exclusivity for Bristol-Myers Squibb and necessitates careful freedom-to-operate analysis for other developers.
Frequently Asked Questions
-
What is the expiration date of US Patent 11,173,209?
The patent was granted on January 11, 2022. Its term extends 20 years from the filing date, which was March 26, 2019. Therefore, the patent is expected to expire on March 26, 2039, subject to any applicable patent term extensions.
-
Does this patent cover all bispecific antibodies that target PD-1 and a TAA?
No, the patent covers specific bispecific binding molecules and methods as defined by its claims. While it covers a class of such molecules, it does not encompass every conceivable bispecific antibody that targets PD-1 and any TAA. The scope is limited by the precise language of the patent's claims, including definitions of binding domains, affinity requirements, and functional characteristics.
-
Can a company develop a bispecific antibody targeting PD-1 and a TAA if it is different from those explicitly mentioned in the patent specification?
The patent claims are the definitive source of protection, not the examples or embodiments within the specification. If a new bispecific antibody, even with a different TAA than those elaborated in the text, falls within the literal scope of the independent claims, it may infringe. A thorough freedom-to-operate analysis is required.
-
What is the significance of the claimed binding affinity of less than or equal to 10 nM for human PD-1?
This specification defines a high-affinity binding characteristic for the PD-1 binding domain. It sets a quantitative threshold that differentiates the claimed antibodies from those with weaker binding to PD-1, likely contributing to enhanced therapeutic efficacy by ensuring robust engagement with the PD-1 receptor.
-
Are there any granted patents that cite US Patent 11,173,209 as prior art?
As a relatively recently granted patent, subsequent patent applications and grants may cite US Patent 11,173,209. A comprehensive patentability search or freedom-to-operate analysis would involve examining patents that cite this patent (forward citations) as well as patents that it references (backward citations) to understand its place within the broader intellectual property landscape.
Citations
[1] Bristol-Myers Squibb Company. (2022). Antibody compositions and methods for treating cancer. U.S. Patent No. 11,173,209. Washington, DC: U.S. Patent and Trademark Office.
